Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines

Cancer Cell International

Norma A Chasseing³  Julian Otaegui⁴  Leandro M Martinez¹  Valeria BFernández Vallone²  Vivian Labovsky² 

[1] Agencia Nacional de Promoción Científica y Tecnológica, Buenos Aires, Argentina;Consejo Nacional de Investigaciones, Científicas y Técnicas (CONICET), Buenos Aires, Argentina;Present address: Vuelta de Obligado 2490, CP 1428, Buenos Aires, Argentina;Laboratorio de Inmuno-Hematología, Instituto de Biología y Medicina Experimental (IBYME), Buenos Aires, Argentina

关键词: Breast cancer cells;    SDF-1;    TRAIL;    RANKL;    OPG;   

Others  :  794900
DOI  :  10.1186/1475-2867-12-29

 received in 2012-03-22, accepted in 2012-06-18,  发布年份 2012

【 摘 要 】

Background

While breast cancer (BC) is the major cause of death among women worldwide, there is no guarantee of better patient survival because many of these patients develop primarily metastases, despite efforts to detect it in its early stages. Bone metastasis is a common complication that occurs in 65-80 % of patients with disseminated disease, but the molecular basis underlying dormancy, dissemination and establishment of metastasis is not understood. Our objective has been to evaluate simultaneously osteoprotegerin (OPG), receptor activator of nuclear factor kappa B ligand (RANKL), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), stromal cell-derived factor-1 (SDF-1), and their receptors (R) in 2 human BC cell lines, MDA-MB-231 and MCF-7.

Methods

OPG, RANKL, TRAIL and SDF-1 expression and release, in addition to the expression of their receptors has been investigated using immunofluorescence, immunocytochemistry and ELISA analyses.

Results

MCF-7 cells released higher levels of OPG in conditioned media (CM) than MDA-MB-231 cells; 100 % of both types of cell expressed OPG, RANKL, TRAIL and SDF-1. Moreover, 100 % in both lines expressed membrane RANKL and RANK, whereas only 50 % expressed CXCR4. Furthermore, 100 % expressed TRAIL-R1 and R4, 30-50 % TRAIL-R2, and 40-55 % TRAIL-R3.

Conclusions

MCF-7 and MDA-MB-231 cells not only released OPG, but expressed RANKL, TRAIL and SDF-1. The majority of the cells also expressed RANK, CXCR4 and TRAIL-R. Since these ligands and their receptors are implicated in the regulation of proliferation, survival, migration and future bone metastasis during breast tumor progression, assessment of these molecules in tumor biopsies of BC patients could be useful in identifying patients with more aggressive tumors that are also at risk of bone metastasis, which may thus improve the available options for therapeutic intervention.

【 授权许可】

   
2012 Labovsky et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 1 .

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

Figure 5 .

Figure 6 .

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
• [2]Bhatia P, Sanders MM, Hansen MF: Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 2005, 11:162-165.
• [3]Kakarala M, Wicha MS: Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008, 26:2813-2820. Review
• [4]Patel SA, Heinrich AC, Reddy BY, Srinivas B, Heidaran N, Rameshwar P: Breast cancer biology: the multifaceted roles of mesenchymal stem cells. J Oncol 2008, 2008:425895.
• [5]Moharita AL, Taborga M, Corcoran KE, Bryan M, Patel PS, Rameshwar P: SDF-1alpha regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis. Blood 2006, 108:3245-3252.
• [6]Nicolin V, Narducci P: Soluble TRAIL could enhance bone destruction acting on Rank-ligand in estrogen-independent human breast cancer cell line MDA-MB-231. Acta Histochem 2010, 112:189-192.
• [7]Jones DH, Nakashima T, Sanchez OH, Kozieradzki I, Komarova SV, Sarosi I, Morony S, Rubin E, Sarao R, Hojilla CV, Komnenovic V, Kong YY, Schreiber M, Dixon SJ, Sims SM, Khokha R, Wada T, Penninger JM: Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
• [8]Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F: Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochim Biophys Acta 2010, 1805:17-24. Review
• [9]Labrinidis A, Liapis V, le Thai M, Atkins GJ, Vincent C, Hay S, Sims NA, Zannettino AC, Findlay DM, Evdokiou A: Does Apo2L/TRAIL play any physiologic role in osteoclastogenesis? Blood 2008, 111:5411-5412.
• [10]Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A: Apo2l/tumor necrosis factor-related apoptosisinducing ligand prevents breast cancer-induced bone destruction in a mouse model. Cancer Res 2006, 66:5363-5370.
• [11]Zauli G, Melloni E, Capitani S, Secchiero P: Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 2009, 66:841-851. Review
• [12]Fili S, Karalaki M, Schaller B: Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors. Cancer Lett 2009, 283(Fili S, Karalaki M, Schaller B):10-19. Review
• [13]Tanaka H, Mine T, Ogasa H, Taguchi T, Liang CT: Expression of RANKL/OPG during bone remodeling in vivo. Biochem Biophys Res Commun 2011, 411:690-694.
• [14]Buckle CH, Neville-Webbe HL, Croucher PI, Lawson MA: Targeting RANK/RANKL in the treatment of solid tumours and myeloma. Curr Pharm Des 2010, 16:1272-1283. Review
• [15]Stanisławowski M, Kmieć Z: The participation of RANK, RANKL and OPG in tumor osteolysis. Postepy Hig Med Dosw (Online) 2009, 63:234-241. Polish
• [16]Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC: Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008, 25:119-129.
• [17]Holland PM, Miller R, Jones J, Douangpanya H, Piasecki J, Roudier M, Dougall WC: Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis. Cancer Biol Ther 2010, 9:539-550.
• [18]Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V, Diamond P, Findlay DM, Zannettino AC, Evdokiou A: Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. J Bone Miner Res 2011, 26:630-643.
• [19]LeBlanc HN, Ashkenazi A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003, 10:66-75. Review
• [20]Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ: Targeting death-inducing receptors in cancer therapy. Oncogene 2007, 26:3745-3757. Review
• [21]Yagita H, Takeda K, Hayakawa Y, Smyth MJ, Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004, 95:777. Review
• [22]Ashkenazi A, Holland P, Eckhardt SG: Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008, 26:3621-3630. Review
• [23]Kruyt FA: TRAIL and cancer therapy. Cancer Lett 2008, 263:14-25. Review
• [24]Zhang Y, Zhang B: TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008, 6:1861-1871.
• [25]Cui DD, Huang Y, Mao SH, Chen SC, Qiu M, Ji LL, Yi C: Synergistic antitumor effect of TRAIL and adriamycin on the human breast cancer cell line MCF-7. Braz J Med Biol Res 2009, 42:854-862.
• [26]Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT: Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001, 61:1645-1651.
• [27]Furusato B, Mohamed A, Uhlén M, Rhim JS: CXCR4 and cancer. Pathol Int 2010, 60:497-505. Review
• [28]Huang M, Li Y, Zhang H, Nan F: Breast cancer stromal fibroblasts promote the generation of CD44 + CD24- cells through SDF-1/CXCR4 interaction. J Exp Clin Cancer Res 2010, 29:80. BioMed Central Full Text
• [29]Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O: Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. Breast Cancer Res Treat 2010, 123:733-745.
• [30]Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A: Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
• [31]Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G: Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002, 99:2703-2711.
• [32]Wang Z, Ma Q, Liu Q, Yu H, Zhao L, Shen S, Yao J: Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer 2008, 99:1695-1703.
• [33]Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550. Review
• [34]Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD: CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604-8612.
• [35]Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME: Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 2011, 71:603-613.
• [36]Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG: Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005, 7:R402-410. BioMed Central Full Text
• [37]Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY: CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005, 12:84-89.
• [38]Schrader AJ, Lechner O, Templin M, Dittmar KE, Machtens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T, Gatzlaff P, Atzpodien J, Buer J, Lauber J: CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 2002, 86:1250-1256.
• [39]Corcoran KE, Trzaska KA, Fernandes H, Bryan M, Taborga M, Srinivas V, Packman K, Patel PS, Rameshwar P: Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS One 2008, 3:e2563.
• [40]Honczarenko M, Le Y, Swierkowski M, Ghiran I, Glodek AM, Silberstein LE: Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors. Stem Cells 2006, 24:1030-1041.
• [41]Juarez J, Bendall L, Bradstock K: Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des 2004, 10:1245-1259. Review
• [42]Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176. Review
• [43]Cross SS, Harrison RF, Balasubramanian SP, Lippitt JM, Evans CA, Reed MW, Holen I: Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables. J Clin Pathol 2006, 59:716-720.
• [44]Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I: Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004, 86:269-279.
• [45]Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE, Holen I: Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. J Clin Pathol 2006, 59:56-63.
• [46]Hofbauer LC, Rachner T, Singh SK: Fatal attraction: why breast cancer cells home to bone. Breast Cancer Res 2008, 10:101. BioMed Central Full Text
• [47]Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G: Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 2011, 6:e19234.
• [48]Brunetti G, Oranger A, Mori G, Sardone F, Pignataro P, Coricciati M, Napoli N, Rizzi R, Liso V, Grassi FR, Grano M, Colucci S: TRAIL effect on osteoclast formation in physiological and pathological conditions. Front Biosci (Elite Ed) 2011, 3:1154-1161.
• [49]Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pignataro P, Tamma R, Grassi FR, Zallone A, Grano M: The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis 2007, 12:1623-1632.
• [50]Romieu-Mourez R, François M, Boivin MN, Bouchentouf M, Spaner DE, Galipeau J: Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype. J Immunol 2009, 182:7963-7973.
• [51]Fernández Vallone V, Choi H, Martinez LM, Labovsky V, Batagelj E, Dimase F, Feldman L, Bordenave RH, Chasseing NA: Osteoclastogenesis process in bone marrow of untreated advanced breast cancer patients [abstract]. Program and Proceedings 2010, 105:B34.
• [52]Martinez LM, Labovsky V: Fernández Vallone VB, Bordenave RH, Feldman L, Chasseing NA: MCS and breast tumor cells [abstract]. Program and Proceedings 2010, 86:A114.
• [53]Velasco CR, Colliec-Jouault S, Redini F, Heymann D, Padrines M: Proteoglycans on bone tumor development. Drug Discovery Today 2010, 15:553-560. Review
• [54]Baud'huin M, Ruiz-Velasco C, Jego G, Charrier C, Gasiunas N, Gallagher J, Maillasson M, Naggi A, Padrines M, Redini F, Duplomb L, Heymann D: Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption. Eur J Cell Biol 2011, 90:49-57.
• [55]Holen I, Shipman CM: Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 2006, 110:279-291. Review
• [56]Kapoor P, Suva LJ, Welch DR, Donahue HJ: Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J Cell Biochem 2008, 103:30-41.
• [57]Brown JM, Zhang J, Keller ET: Opg, RANKl, and RANK in cancer metastasis: expression and regulation. Cancer Treat Res 2004, Review:149-172. Review
• [58]Patsialou A, Wyckoff J, Wang Y, Goswami S, Stanley ER, Condeelis JS: Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res 2009, 69:9498-9506.
• [59]Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y, Amadori D: Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer Patients. Clin Breast Cancer 2011, 11:369-375.
• [60]Ponte AL, Marais E, Gallay N, Langonné A, Delorme B, Hérault O, Charbord P, Domenech J: The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 2007, 25:1737-1745.
• [61]Sanliogliu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, Griffith TS, Sanlioglu S: TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007, 69:716-723.
• [62]Kimberley FC, Screaton GR: Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004, 14:359-372. Review
• [63]Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O: Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006, 26:7046-7055.